EA201201586A1 - ANTI-TUMOR MEDICINE (OPTIONS) - Google Patents
ANTI-TUMOR MEDICINE (OPTIONS)Info
- Publication number
- EA201201586A1 EA201201586A1 EA201201586A EA201201586A EA201201586A1 EA 201201586 A1 EA201201586 A1 EA 201201586A1 EA 201201586 A EA201201586 A EA 201201586A EA 201201586 A EA201201586 A EA 201201586A EA 201201586 A1 EA201201586 A1 EA 201201586A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bortezomib
- creation
- minerals
- antitumor agent
- isotopes
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к области фармацевтической промышленности и медицине и может быть использовано при создании и применении противоопухолевых средств, в частности ингибиторов протеасом на основе бортезомиба. Задачей настоящего изобретения является создание эффективного противоопухолевого средства на базе бортезомиба с расширенными свойствами при использовании. Задача решается за счет того, что противоопухолевое средство содержит бортезомиб, минеральные вещества калий, железо, изотопы углеродаС, изотопы азотаN. Техническими результатами изобретения являются увеличение лечебного эффекта без увеличения концентрации бортезомиба при лечении злокачественных опухолей за счет использования в противоопухолевом средстве изотоповС,N и минеральных веществ; увеличение времени хранения, в том числе в готовом к применению жидком виде.The invention relates to the pharmaceutical industry and medicine and can be used in the creation and application of anticancer drugs, in particular bortezomiba-based proteasome inhibitors. The present invention is the creation of an effective anticancer agent on the basis of bortezomib with enhanced properties during use. The problem is solved due to the fact that the antitumor agent contains bortezomib, minerals potassium, iron, carbon isotopes, nitrogen isotopesN. Technical results of the invention are to increase the therapeutic effect without increasing the concentration of bortezomib in the treatment of malignant tumors due to the use in the antitumor agent isotopes C, N and minerals; increase storage time, including in ready-to-use liquid form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201201586A EA201201586A1 (en) | 2012-12-24 | 2012-12-24 | ANTI-TUMOR MEDICINE (OPTIONS) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201201586A EA201201586A1 (en) | 2012-12-24 | 2012-12-24 | ANTI-TUMOR MEDICINE (OPTIONS) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201201586A1 true EA201201586A1 (en) | 2014-06-30 |
Family
ID=51013724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201201586A EA201201586A1 (en) | 2012-12-24 | 2012-12-24 | ANTI-TUMOR MEDICINE (OPTIONS) |
Country Status (1)
| Country | Link |
|---|---|
| EA (1) | EA201201586A1 (en) |
-
2012
- 2012-12-24 EA EA201201586A patent/EA201201586A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201807411T4 (en) | DNA-PK inhibitors. | |
| EA201691059A1 (en) | PEPTIDOMYMETICS COMPOUNDS AND THEIR CONJUGATES CONTAINING ANTIBODY AND MEDICINE | |
| MX2021007651A (en) | Ezh2 inhibitors for treating lymphoma. | |
| MX2017015896A (en) | Anticancer agent. | |
| UY35082A (en) | OXYGEN CARRIER SUBSTANCE BASED ON HEMOGLOBIN CONTAINING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER AND THE PREVENTION OF CANCER RECURRENCE | |
| MX2019005623A (en) | Dose and regimen for hdm2-p53 interaction inhibitors. | |
| EA201201654A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201586A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201588A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201616A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201584A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201655A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201590A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201587A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201589A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201585A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| NZ725067A (en) | Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| MD596Y (en) | Method for treating the chronic viral hepatitis C | |
| EA201300373A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201300370A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| RU2014146031A (en) | Pharmaceutical gel based on doxorubicin and organosilicon niosomes-niosomes for the treatment of skin cancer | |
| EA201992500A3 (en) | Salts and Drugs of 1-Methyl-D-Tryptophan | |
| EA201300371A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| MD854Z (en) | Method for treating locally advanced II-III stage cervical canrcinoma | |
| EA201201208A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) |